Budapest, Hungary – 30 April 2022: A method for delivering genetic material to the body is being tested as a way to repair damaged heart muscle after a heart attack. The ground-breaking research is presented today at Frontiers in CardioVascular Biomedicine 2022, a scientific congress of the European Society of Cardiology (ESC).1
The COVID-19 messenger RNA (mRNA) vaccines2 use lipid nanoparticles (tiny fat droplets) to deliver mRNA to the body’s cells. This mRNA instructs the cells to manufacture a dummy spike protein on their surface to mimic the protein on the virus causing COVID-19. The body then mounts an immune response by creating antibodies which can be used if the individual becomes infected with the virus.
A similar method for mRNA delivery was used in the current study. However, instead of aiming for an immune response, the researchers’ ultimate goal is to instruct the heart’s cells to repair themselves after a heart attack.
This preliminary study was conducted to determine whether mRNA could be successfully delivered to the heart muscle in lipid nanoparticles. The researchers injected different formulations into the left ventricular wall of mouse hearts during open chest surgery under general anaesthesia. Twenty-four hours after administration, the mice were sacrificed and the location of mRNA translation was examined.
The researchers found that mRNA successfully reached the heart cells 24 hours after injection. However, despite injection into the heart, the highest levels of mRNA translation were found in cells of the liver and spleen.
Study author Dr. Clara Labonia of the University Medical Center Utrecht, the Netherlands said: “High expression was expected in the liver, since it metabolises the lipid nanoparticles. Nonetheless, it was encouraging to see that there was mRNA translation in the heart tissue which means that lipid nanoparticles could work as delivery systems for mRNA therapy.”
She concluded: “The next step of this research is to test more formulations and choose the one which most efficiently targets the heart tissue. We will then assess whether delivery of mRNA to mice with ischaemic hearts (resembling a heart attack) has any therapeutic effect.”
ENDS
Authors: ESC Press Office
Mobile: +33 (0)7 8531 2036
Email: [email protected]
Follow us on Twitter @ESCardioNews
Notes to editor
Funding: Funding was provided by the Dutch Heart Foundation (Dr. E. Dekker Senior Scientist grant, no. 2019T049).
Disclosures: None.
References and notes
1The abstract “Modified mRNA delivery to the heart using lipid nanoparticles” will be presented during the session “Young Investigator Award – Novelties in cardiovascular disease mechanism” which takes place on 30 April at 11:30 CEST in Lecture Room 3.
2The COVID-19 mRNA vaccines include Pfizer-BioNTech and Moderna.
About Frontiers in CardioVascular Biomedicine (FCVB) #FCVB2022
Frontiers in CardioVascular Biomedicine (FCVB) is the biennial congress of the ESC Council on Basic Cardiovascular Science (CBCS), which works to bridge the gap between science and clinical practice. FCVB is hosted by the CBCS in collaboration with 14 ESC Working Groups and European cardiovascular science societies.
About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.
Information for journalists attending FCVB 2022
FCVB 2022 takes place 29 April to 1 May at Semmelweis University in Budapest, Hungary. Explore the scientific programme.
- Free registration applies to accredited press.
- Credentials: A valid press card or appropriate letter of assignment with proof of three recent published articles. Read the ESC media and embargo policy.
- The ESC Press Office will verify the documents and confirm by email that your press accreditation is valid.
- The ESC Press Office decision is final regarding all press registration requests.
